BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36151009)

  • 1. Radioiodine therapy in the different stages of differentiated thyroid cancer.
    Valerio L; Maino F; Castagna MG; Pacini F
    Best Pract Res Clin Endocrinol Metab; 2023 Jan; 37(1):101703. PubMed ID: 36151009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
    Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
    Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
    Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
    Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal Timing of Initiating Dynamic Risk Stratification During the Early Postoperative Period in Patients with Differentiated Thyroid Carcinoma After Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Park JH; Moon GS; Nam KT; Yoon JH
    Ann Surg Oncol; 2021 Oct; 28(11):6580-6589. PubMed ID: 33677764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the abilities of staging and risk stratification systems to predict the long-term structural recurrence in patients with differentiated thyroid carcinoma after total thyroidectomy and radioactive iodine remnant ablation.
    Nam KT; Park JH; Moon GS; Yoon JH
    Gland Surg; 2021 Jul; 10(7):2200-2210. PubMed ID: 34422591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer.
    Juweid ME; Tulchinsky M; Mismar A; Momani M; Zayed AA; Al Hawari H; Albsoul N; Mottaghy FM
    Int J Cancer; 2020 Nov; 147(9):2345-2354. PubMed ID: 32319676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
    Lind P; Igerc I; Kohlfürst S
    Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.
    Trimboli P; Piccardo A; Signore A; Valabrega S; Barnabei A; Santolamazza G; Di Paolo A; Stati V; Chiefari A; Vottari S; Simmaco M; Ferrarazzo G; Ceriani L; Appetecchia M; Giovanella L
    Thyroid; 2020 May; 30(5):713-719. PubMed ID: 31973653
    [No Abstract]   [Full Text] [Related]  

  • 12. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
    Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
    J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poorly differentiated thyroid cancer in the context of the revised 2015 American Thyroid Association Guidelines and the Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System (eighth edition).
    Walczyk A; Kopczyński J; Gąsior-Perczak D; Pałyga I; Kowalik A; Chrapek M; Hejnold M; Góźdź S; Kowalska A
    Clin Endocrinol (Oxf); 2019 Aug; 91(2):331-339. PubMed ID: 30525210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
    Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
    Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Draft of the best medical treatment in patients with low-risk thyroid cancer].
    Vlček P; Nováková D; Vejvalka J; Zimák J; Křenek M; Vošmiková K; Smutný S; Bavor P; Astl J; Lukáš J
    Vnitr Lek; 2015 Sep; 61(9):769-77. PubMed ID: 26465275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
    Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
    J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioactive iodine ablation post differentiated thyroid cancer surgery: an analysis of use and impact of the American Thyroid Association guidelines.
    Sia Y; Dave RV; Nour D; Miller JA; Skandarajah AR; Tasevski R
    ANZ J Surg; 2019 Nov; 89(11):E502-E506. PubMed ID: 31674140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study.
    Liu X; Fan Y; Liu Y; He X; Zheng X; Tan J; Jia Q; Meng Z
    Updates Surg; 2020 Sep; 72(3):871-884. PubMed ID: 32342347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
    Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
    Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.